Germany Insulin Infusion Pump Market Size and Share
Germany Insulin Infusion Pump Market Analysis by Mordor Intelligence
The Germany Insulin Infusion Pump Market size is projected to expand from USD 137.68 million in 2026 and USD 141.32 million in 2027 to USD 160.98 million by 2032, registering a CAGR of 2.64% between 2027 and 2032.
Diabetes patients are more likely than non-diabetics to have significant problems. Diabetic medicine makers took care during COVID-19 to ensure that pharmaceuticals were delivered to diabetic patients with the assistance of local governments. "Since the start of COVID-19, our commitment to patients, our employees, and the communities where we operate has remained unchanged," Novo Nordisk stated on its website. "We continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19."
Germany is one of the industrialized nations with cutting-edge medical facilities. Diabetes mellitus is classified into several categories. Hyperglycemia, or high blood sugar, is a typical new-onset symptom. The most common types of diabetes include type-1 diabetes, type-2 diabetes, and gestational diabetes. Other types occur on a less frequent basis. Type-2 diabetes will grow increasingly common in Germany during the next twenty years. According to DZD experts, up to 12 million people may develop a metabolic illness by 2040. The fast growth in type-1 and type-2 diabetes among the elderly poses considerable challenges for the German healthcare system.
Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have an increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications. Germany is one of the developed countries and advanced in terms of healthcare facilities. Technologies, such as insulin infusion pumps and continuous glucose monitoring are getting more adopted rapidly in Germany than the other developing countries. Moreover, the reimbursement policy and the pricing policy are highly regulated, which drives the market and increases the adoption rate of new and advanced technologies.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Germany Insulin Infusion Pump Market Trends and Insights
Insulin Pump is Expected to Witness Growth Over the Forecast Period
In the Germany insulin infusion pump market, insulin pumps deliver insulin continuously or on demand, mimicking the function of the human pancreas. These devices can replace daily insulin injections or insulin pens. Insulin pump therapy is a widely adopted insulin delivery method for people with type 1 diabetes mellitus (T1DM). Insulin infusion pumps provide a proven treatment option for T1DM patients across all age groups by enabling near-physiological insulin delivery when the pancreas does not produce sufficient insulin. Remote-controlled insulin pumps also allow parents to suspend insulin delivery or administer bolus doses from a safe distance while their child is playing or eating.
Insulin pump therapy is very important for children and adolescents with type 1 diabetes, and clinical recommendations strongly recommend it. The regularity with which glucose levels are monitored is determined by the type of diabetes, which varies from patient to patient. Type-1 diabetes patients must check their blood glucose levels regularly, monitor them, and modify their insulin dose accordingly, expected to drive market growth throughout the projected period. Continuous subcutaneous insulin infusion and glucose monitoring devices have significantly improved patient care and quality of life and are now routinely utilized in ambulatory care. This technology is increasingly being employed in the healthcare setting.
In Germany, insulin pump treatment was used by more than half of children and adolescents with type-1 diabetes. Insulin pump use has steadily grown, with females outnumbering boys. Insulin pump treatment allows persons with type-1 diabetes more freedom and more physiological insulin delivery. According to research, insulin pump treatment can improve blood sugar management. Owing to the above factors, the market will likely continue to grow.
Rising diabetes prevalence in the country is anticipated to boost the market studied
In recent years, Germany has seen an alarming increase in the prevalence of diabetes. Patients with diabetes must make several adjustments during the day to maintain minimal blood glucose levels. These adjustments include taking anti-diabetic medication or eating more carbs while monitoring their blood glucose levels. Obesity, a poor diet, and physical inactivity contribute to a rise in newly diagnosed Type-1 and Type-2 diabetes cases. The fast-growing incidence and prevalence of diabetes patients and healthcare spending are indicators of increased diabetic device use. Strict government controls and favorable WHO regulations controlling the use of insulin pumps in Germany stimulate companies to develop unique products. The availability of these companies on the German market facilitates the conduct of clinical trials by regional clinical research organizations (CROs). It provides management simplicity, which speeds up the discovery process. According to the German Diabetes Centre (DDZ), at least 7.2% of the German population now has diabetes, which is expected to rise dramatically over the next two decades. Under German law, public insurance must limit out-of-pocket healthcare expenditures and cover all medically required treatment, including insulin. According to T1 International, an advocacy organization for persons with type-1 diabetes, German diabetes patients enjoy among the lowest out-of-pocket insulin prices in the world.
Diabetes, a significant health concern, is one of the astonishing difficulties confronting Germany's healthcare facilities. The prevalence of recognized type-1 and type-2 diabetes in the German adult population is rather high, with many people who have not yet been diagnosed. The incidence of type-2 diabetes is expected to climb gradually in the coming years due to an aging population and an unhealthy lifestyle. High-quality therapy, including adequate monitoring, risk factor reduction, and active self-management, is essential in reducing complications in German type-2 diabetes patients.
As a consequence of the factors above, the investigated market is predicted to grow during the investigation.
Competitive Landscape
Market Concentration
Due to the existence of only a few big businesses operating internationally and locally, the insulin infusion pump industry is concentrated. The competitive landscape includes examining a few well-known worldwide and local organizations, such as Medtronic PLC, Insulet Corporation, Ypsomed, Ascensia Diabetes Care, and Tandem Diabetes Care.
Germany Insulin Infusion Pump Industry Leaders
-
Medtronics
-
Ascensia Diabetes Care
-
Insulet Corporation
-
Tandem Diabetes Care
-
Ypsomed
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- June 2023: Novo Nordisk entered exclusive negotiations for a controlling stake in BIOCORP, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in BIOCORP. BIOCORP is a French company specializing in the design, development, and manufacturing of delivery systems and innovative medical devices, including Mallya, a Bluetooth-enabled smart add-on device for pen injectors.
- May 2023: Medtronic plc announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch device - a tubeless, wearable, and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology algorithm and next-generation continuous glucose monitor (CGM), is expected to expand the company's ability to address the needs of more individuals with diabetes.
Germany Insulin Infusion Pump Market Report Scope
An insulin pump delivers insulin to control blood sugar and minimize hypoglycemia's effects. The pump comprises a pump reservoir like an insulin cartridge, a battery-operated pump, and a computer chip that allows the user to control the exact amount of insulin being delivered. The pump is attached to a thin plastic tube (an infusion set) with a soft cannula (or needle) at the end through which insulin passes. Germany's insulin infusion pumps market is segmented by component (pump device, infusion set, and reservoir). The report offers the value (USD) and Volume (units) for the above segments.
| Insulin Pump Device |
| Infusion Set |
| Reservoir |
| Insulin Infusion Pump | Insulin Pump Device |
| Infusion Set | |
| Reservoir |
Key Questions Answered in the Report
How big is the Germany Insulin Infusion Pump Market?
The Germany Insulin Infusion Pump Market size is expected to reach USD 141.32 million in 2027 and grow at a CAGR of 2.64% to reach USD 160.98 million by 2032.
What is the current Germany Insulin Infusion Pump Market size?
In 2026, the Germany Insulin Infusion Pump Market size is expected to reach USD 137.68 million.
Who are the key players in Germany Insulin Infusion Pump Market?
Medtronics, Ascensia Diabetes Care, Insulet Corporation, Tandem Diabetes Care and Ypsomed are the major companies operating in the Germany Insulin Infusion Pump Market.
What years does this Germany Insulin Infusion Pump Market cover, and what was the market size in 2025?
In 2025, the Germany Insulin Infusion Pump Market size was estimated at USD 134.14 million. The report covers the Germany Insulin Infusion Pump Market historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the Germany Insulin Infusion Pump Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.